EC Number   |
General Information |
Reference |
|---|
   3.4.17.23 | drug target |
ACE2-based therapeutics confer a broad-spectrum neutralization potency for ACE2-tropic viruses, including SARS-CoV-2 variants |
763405 |
| 3.4.17.23 | drug target |
angiotensin converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, but only ACE2 of certain species can be utilized by SARS-CoV-2. SARS-CoV-2 tends to utilize ACE2 of various mammals, except murines, and some birds, such as pigeon. This prediction may help to screen the intermediate hosts of SARS-CoV-2. SARS-CoV-2 has a high genetic relationship with a bat coronavirus (BatCoV RaTG13) with a 96% genomic nucleotide sequence identity. The close phylogenetic relationship to Bat RaTG13 provides evidence for a bat origin of SARS-CoV-2. Direct transmission of the virus from bats to humans is unlikely due to the lack of direct contact between bats and humans (in Wuhan, China). There are probably intermediate hosts transmitting SARS-CoV-2 to humans. Combined phylogenetic analysis and critical site marking is used to predict the utilizing capability of ACE2 from different animal species by SARS-CoV-2. It is confirmed that pangolin (Manis javanica), cat (Felis catus), cow (Bos taurus), buffalo (Bubalus bubalis), goat (Capra hircus), sheep (Ovis aries) and pigeon (Columba livia) ACE2 might be utilized by SARS-CoV-2, indicating potential interspecies transmission of the virus from bats to these animals and among these animals |
754646 |
| 3.4.17.23 | drug target |
angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication |
753315 |
| 3.4.17.23 | drug target |
antibodies and small molecular inhibitors that can block the interaction of the enzyme (ACE2) with the receptor binding domain can to combat the virus SARS-CoV-2 |
752692 |
| 3.4.17.23 | drug target |
coronaviruses use the receptor-binding domain (RBD) of their glycosylated S protein to bind to cell specific surface receptors and initiate membrane fusion and virus entry. For both SARS-CoV and SARS-CoV-2, this involves binding to human angiotensin converting enzyme 2 (hACE2) followed by proteolytic activation by human proteases. Blockade of the receptor-binding domain-hACE2 protein-protein interaction (PPI) can disrupt infection efficiency. Screening of organic dyes and related novel druglike compounds leads to the identification of several small-molecule compounds showing promising broad-spectrum inhibition of the protein-protein interaction between coronavirus spike proteins and their cognate ACE2 receptor. Several of them, including dyes, such as Congo red and direct violet 1, but especially novel nondye compounds, such as DRI-23041 are able to inhibit the entry of SARSCoV-2-S expressing pseudoviruses into ACE2-expressing cells in a concentration-dependent manner |
762549 |
| 3.4.17.23 | drug target |
Food and Drug administration(FDA) approved drugs are examined for inhibiting serine protease TMPRSS2 and human ACE. Valrubicin and lopinavir have the least degree of toxicity |
763002 |
| 3.4.17.23 | drug target |
polyunsaturated fatty acids most effectively interfere with binding to hACE2, the receptor for SARSCoV-2. Using a spike protein pseudo-virus, linolenic acid and eicosapentaenoic acid significantly block the entry of SARS-CoV-2. In addition, eicosapentaenoic acid shows higher efficacy than linolenic acid in reducing activity of TMPRSS2 and cathepsin L proteases, but neither of the fatty acids affected their expression at the protein level. Also, neither reduction of hACE2 activity nor binding to the hACE2 receptor upon treatment with these two fatty acids is observed |
763707 |
| 3.4.17.23 | drug target |
potential therapeutic approach to ACE2-mediated COVID-19. Treatment with a soluble form of ACE2 may exert dual functions, slow viral entry into cells and hence viral spread and protect the lung from injury |
753944 |
| 3.4.17.23 | drug target |
SARS-CoV-2 spike protein uses the angiotensin converting enzyme 2 (ACE2) as a cellular receptor to initiate infection. Compounds that interfere with the SARS-CoV-2 spike protein receptor binding domain protein (RBD)-ACE2 receptor interaction may function as entry inhibitors |
763416 |
| 3.4.17.23 | drug target |
the enzyme (ACE2) plays an important role, facilitating the movement of SARSCoV-2 through the cell membrane. ED compound (Chembridge ID 7781334) will provide the basis for developing a drug that interacts with the angiotensin-converting enzyme 2 (ACE2). Drugs based on ED could hinder or prevent the interaction of ACE2 with SARS-CoV-2 |
762938 |
